MIRA Pharmaceuticals, Inc. (MIRA) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

MIRA Pharmaceuticals, Inc. (MIRA) closed at USD 0.66 on 2026-10-15, a change of -59.4 % over the past year, with a market capitalization of USD 26.57M.

MIRA Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MIRA Pharmaceuticals, Inc. key figures

Previous close

USD 0.66 (2026-10-15)

1-year change

-59.4 %

Market cap

USD 26.57M

Enterprise value

USD 18.46M

P/E ratio (trailing)

-0.56

P/E ratio (forward)

-1.54

EPS (trailing)

-1.14

EPS (forward)

-0.41

PEG ratio

n/a

Price to book

3.26

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.27

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MIRA Pharmaceuticals, Inc. and compare it with other stocks.